ENFN241220P7500
- 0.00
- 0.000.00%
Enfusion Newsroom
Enfusion To Present at Upcoming Investor Events
An Intrinsic Calculation For Enfusion, Inc. (NYSE:ENFN) Suggests It's 38% Undervalued
There May Be Some Bright Spots In Enfusion's (NYSE:ENFN) Earnings
Morgan Stanley Maintains Enfusion(ENFN.US) With Buy Rating, Maintains Target Price $11
Enfusion: A Strategic Opportunity With High Growth Potential and Attractive Valuation
Analysts Offer Insights on Technology Companies: Block (SQ), Silicon Laboratories (SLAB) and Enfusion (ENFN)
Stifel Maintains Enfusion(ENFN.US) With Buy Rating, Raises Target Price to $11
Enfusion | 10-Q: Q3 2024 Earnings Report
Enfusion: Strong Client Acquisitions and Strategic Positioning Drive Buy Rating
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript Summary
Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript
William Blair Maintains Enfusion(ENFN.US) With Buy Rating
William Blair Remains a Buy on Enfusion (ENFN)
Express News | Enfusion Inc - Q3 Rev $51.2 Mln
Enfusion Q3 Adjusted Earnings, Revenue Increase; 2024 Revenue Guidance Narrowed
Enfusion Narrows FY2024 Sales Guidance From $200.00M-210.00M to $202.00M-205.00M VS Est. 204.8M
Enfusion Non-GAAP EPS of $0.05 Misses by $0.01, Revenue of $51.17M Misses by $1M
Earnings Preview: Enfusion to Report Financial Results Pre-market on November 04
$Enfusion(ENFN.US)$ is scheduled to release its financial results pre-market on November 04 ET. Earnings PreviewAnalysts estimate $Enfusion(ENFN.US)$ to post revenue of USD52.17M for 2024Q3, up 17.61%
FTV Capital Named to Inc.'s Founder-Friendly Investors List for Fourth Consecutive Year
Enfusion, Inc.'s (NYSE:ENFN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?